AbbVie closes in on Biohaven with new migraine prevention OK for oral CGRP drug
You can now add another hefty pharma player to the commercial battle for migraine prevention.
AbbVie has landed an approval for Qulipta, the oral CGRP receptor antagonist it obtained via the $63 billion buyout of Allergan and the third FDA-approved drug in its migraine portfolio.
While AbbVie’s other CGRP drug, Ubrelvy, won an OK for acute treatment of migraine ahead of Biohaven, the Yale biotech spinout snared a leg up this May when it scored an expanded label for Nurtec to cover the preventative use.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.